Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the study drugs, lenvatinib and pembrolizumab, are
effective in treating advanced Adenoid Cystic Carcinoma (ACC) or other salivary gland cancers
that have come back and/or spread to other parts of the body. Researchers are also doing this
study to test the safety of the study drugs in participants.